Published in Antimicrob Agents Chemother on May 14, 2012
Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis. Front Physiol (2015) 1.00
Rifaximin modulates the vaginal microbiome and metabolome in women affected by bacterial vaginosis. Antimicrob Agents Chemother (2014) 0.92
Vaginal microbiome and metabolome highlight specific signatures of bacterial vaginosis. Eur J Clin Microbiol Infect Dis (2015) 0.84
Longitudinal analysis reveals characteristically high proportions of bacterial vaginosis-associated bacteria and temporal variability of vaginal microbiota in northern pig-tailed macaques (Macaca leonina). Dongwuxue Yanjiu (2015) 0.79
Development of a microarray-based tool to characterize vaginal bacterial fluctuations and application to a novel antibiotic treatment for bacterial vaginosis. Antimicrob Agents Chemother (2015) 0.78
Microbicides for the Treatment of Sexually Transmitted HIV Infections. J Pharm (Cairo) (2014) 0.76
Novel approaches for the taxonomic and metabolic characterization of lactobacilli: Integration of 16S rRNA gene sequencing with MALDI-TOF MS and 1H-NMR. PLoS One (2017) 0.75
Improvement of abnormal vaginal flora in Ugandan women by self-testing and short use of intravaginal antimicrobials. Eur J Clin Microbiol Infect Dis (2016) 0.75
Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol (1991) 20.49
Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med (1983) 16.63
Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A (2010) 12.39
Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med (2005) 11.23
Fast and sensitive silver staining of DNA in polyacrylamide gels. Anal Biochem (1991) 9.26
Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis (1999) 6.85
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis (2006) 5.96
Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol (2004) 4.53
Detection and identification of gastrointestinal Lactobacillus species by using denaturing gradient gel electrophoresis and species-specific PCR primers. Appl Environ Microbiol (2000) 4.01
Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. Appl Environ Microbiol (2004) 3.51
Molecular diversity of Lactobacillus spp. and other lactic acid bacteria in the human intestine as determined by specific amplification of 16S ribosomal DNA. Appl Environ Microbiol (2002) 3.43
Development of 16S rRNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces. Appl Environ Microbiol (2002) 3.35
Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis (2003) 3.24
Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin Infect Dis (2003) 3.20
Diversity of human vaginal bacterial communities and associations with clinically defined bacterial vaginosis. Appl Environ Microbiol (2008) 2.73
The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG (2011) 2.41
Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy. BJOG (2009) 2.38
Adherent biofilms in bacterial vaginosis. Obstet Gynecol (2005) 2.31
Changes in vaginal bacterial concentrations with intravaginal metronidazole therapy for bacterial vaginosis as assessed by quantitative PCR. J Clin Microbiol (2009) 2.29
Amine content of vaginal fluid from untreated and treated patients with nonspecific vaginitis. J Clin Invest (1979) 2.25
Cultivation-independent analysis of changes in bacterial vaginosis flora following metronidazole treatment. J Clin Microbiol (2007) 2.06
Molecular analysis of the diversity of vaginal microbiota associated with bacterial vaginosis. BMC Genomics (2010) 2.04
Bacterial vaginosis. Annu Rev Med (2000) 1.98
Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother (2010) 1.79
Bacterial vaginosis: microbiological and clinical findings. Eur J Clin Microbiol (1987) 1.71
Quantitative PCR assessments of bacterial species in women with and without bacterial vaginosis. J Clin Microbiol (2010) 1.69
Detection of bacterial vaginosis-related organisms by real-time PCR for Lactobacilli, Gardnerella vaginalis and Mycoplasma hominis. FEMS Immunol Med Microbiol (2002) 1.54
Heterogeneity of vaginal microbial communities within individuals. J Clin Microbiol (2009) 1.50
Selection and identification of anaerobic lactobacilli producing inhibitory compounds against vaginal pathogens. FEMS Immunol Med Microbiol (2006) 1.48
Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy (2005) 1.27
The aetiology of bacterial vaginosis. J Appl Microbiol (2011) 1.22
Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis (1993) 1.21
Dynamics of vaginal bacterial communities in women developing bacterial vaginosis, candidiasis, or no infection, analyzed by PCR-denaturing gradient gel electrophoresis and real-time PCR. Appl Environ Microbiol (2007) 1.17
In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria. Antimicrob Agents Chemother (2003) 1.14
Quantitative variations in the vaginal bacterial population associated with asymptomatic infections: a real-time polymerase chain reaction study. Eur J Clin Microbiol Infect Dis (2008) 1.10
Aerobic vaginitis in pregnancy. BJOG (2011) 1.08
Diversity of cervicovaginal microbiota associated with female lower genital tract infections. Microb Ecol (2011) 1.01
Lactobacilli in the female genital tract in relation to other genital microbes and vaginal pH. Acta Obstet Gynecol Scand (2006) 1.00
Rifaximin: new therapeutic indication and future directions. Clin Ther (2011) 1.00
The relationship between periodontal disease, bacterial vaginosis, and preterm birth. J Perinat Med (2007) 0.99
The vaginal ecosystem. Am J Obstet Gynecol (1991) 0.92
Classification of the genus Mobiluncus based on comparative partial 16S rRNA gene analysis. Int J Syst Bacteriol (1996) 0.91
Correlation of Atopobium vaginae Amount With Bacterial Vaginosis Markers. J Low Genit Tract Dis (2012) 0.86
Anti-anaerobic activity of antibacterial agents. Expert Opin Investig Drugs (2001) 0.82
Local treatment of bacterial vaginosis with a bioadhesive metronidazole tablet. Eur J Obstet Gynecol Reprod Biol (2002) 0.79
Asymptomatic bacterial vaginosis: response to therapy. Am J Obstet Gynecol (2000) 0.77
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology (2003) 4.40
A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med (2014) 3.92
Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One (2010) 3.64
Mental Disorders in People Affected by Thalidomide. Dtsch Arztebl Int (2017) 2.01
Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother (2010) 1.79
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin (2011) 1.65
Paracetamol: new vistas of an old drug. CNS Drug Rev (2007) 1.63
Prevalence of bacterial vaginosis and vaginal flora changes in peri- and postmenopausal women. J Clin Microbiol (2002) 1.59
Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol (2003) 1.51
Interrelationships of interleukin-8 with interleukin-1beta and neutrophils in vaginal fluid of healthy and bacterial vaginosis positive women. Mol Hum Reprod (2003) 1.48
Unbalance of intestinal microbiota in atopic children. BMC Microbiol (2012) 1.37
Aging of the human metaorganism: the microbial counterpart. Age (Dordr) (2011) 1.36
Facts and myths on recurrent vulvovaginal candidosis--a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy. Int J STD AIDS (2002) 1.24
Dynamics of vaginal bacterial communities in women developing bacterial vaginosis, candidiasis, or no infection, analyzed by PCR-denaturing gradient gel electrophoresis and real-time PCR. Appl Environ Microbiol (2007) 1.17
Prevention of TNBS-induced colitis by different Lactobacillus and Bifidobacterium strains is associated with an expansion of gammadeltaT and regulatory T cells of intestinal intraepithelial lymphocytes. Inflamm Bowel Dis (2009) 1.16
Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis (2002) 1.15
Bacterial vaginosis: a review on clinical trials with probiotics. New Microbiol (2013) 1.14
Semen preparation methods and sperm apoptosis: swim-up versus gradient-density centrifugation technique. Fertil Steril (2008) 1.13
Antimicrobial and antitumor activity of N-heteroimmine-1,2,3-dithiazoles and their transformation in triazolo-, imidazo-, and pyrazolopirimidines. Bioorg Med Chem (2002) 1.13
High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum (2007) 1.12
Effect of a synbiotic food consumption on human gut metabolic profiles evaluated by (1)H Nuclear Magnetic Resonance spectroscopy. Int J Food Microbiol (2009) 1.12
Metabolic signatures of extreme longevity in northern Italian centenarians reveal a complex remodeling of lipids, amino acids, and gut microbiota metabolism. PLoS One (2013) 1.11
Impact of a synbiotic food on the gut microbial ecology and metabolic profiles. BMC Microbiol (2010) 1.10
Ageing and gut microbes: perspectives for health maintenance and longevity. Pharmacol Res (2012) 1.09
Perineal ultrasound evaluation of urethral angle and bladder neck mobility in women with stress urinary incontinence. BJOG (2002) 1.06
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS One (2013) 1.04
Bifidobacterial enolase, a cell surface receptor for human plasminogen involved in the interaction with the host. Microbiology (2009) 1.04
Proteomic analysis of human cervical-vaginal fluids. J Proteome Res (2007) 1.04
The effects of mediolateral episiotomy on pelvic floor function after vaginal delivery. Obstet Gynecol (2004) 1.04
DnaK from Bifidobacterium animalis subsp. lactis is a surface-exposed human plasminogen receptor upregulated in response to bile salts. Microbiology (2010) 1.03
Binding of human plasminogen to Bifidobacterium. J Bacteriol (2007) 1.02
High taxonomic level fingerprint of the human intestinal microbiota by ligase detection reaction--universal array approach. BMC Microbiol (2010) 1.01
Intestinal microbiota is a plastic factor responding to environmental changes. Trends Microbiol (2012) 1.00
Real-time PCR quantification of bacterial adhesion to Caco-2 cells: competition between bifidobacteria and enteropathogens. Res Microbiol (2005) 1.00
Human intestinal microbiota: cross-talk with the host and its potential role in colorectal cancer. Crit Rev Microbiol (2010) 0.99
Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomedicine (2009) 0.99
Brain effects of melanocortins. Pharmacol Res (2008) 0.99
Parametric evaluation of heart rate variability during the menstrual cycle in young women. Biomed Sci Instrum (2005) 0.99
Functional intestinal microbiome, new frontiers in prebiotic design. Int J Food Microbiol (2010) 0.98
An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol (2003) 0.97
Effects of third-generation oral contraceptives on high-sensitivity C-reactive protein and homocysteine in young women. Obstet Gynecol (2008) 0.97
Correlation of local interleukin-1beta levels with specific IgA response against Gardnerella vaginalis cytolysin in women with bacterial vaginosis. Am J Reprod Immunol (2002) 0.96
VE-cadherin is a critical molecule for trophoblast-endothelial cell interaction in decidual spiral arteries. Exp Cell Res (2005) 0.96
Oxalate-degrading activity in Bifidobacterium animalis subsp. lactis: impact of acidic conditions on the transcriptional levels of the oxalyl coenzyme A (CoA) decarboxylase and formyl-CoA transferase genes. Appl Environ Microbiol (2010) 0.96
Functional metagenomic profiling of intestinal microbiome in extreme ageing. Aging (Albany NY) (2013) 0.95
Characterization and heterologous expression of the oxalyl coenzyme A decarboxylase gene from Bifidobacterium lactis. Appl Environ Microbiol (2004) 0.93
Potential probiotic Kluyveromyces marxianus B0399 modulates the immune response in Caco-2 cells and peripheral blood mononuclear cells and impacts the human gut microbiota in an in vitro colonic model system. Appl Environ Microbiol (2011) 0.93
Effects of probiotic bacteria on gastrointestinal motility in guinea-pig isolated tissue. World J Gastroenterol (2006) 0.93
Quantitative detection of probiotic Bifidobacterium strains in bacterial mixtures by using real-time PCR. Syst Appl Microbiol (2003) 0.91
Metagenomics: key to human gut microbiota. Dig Dis (2011) 0.91
A proteomic view of Bifidobacterium infantis generated by multi-dimensional chromatography coupled with tandem mass spectrometry. Proteomics (2005) 0.90
Correlation of local interleukin-8 with immunoglobulin A against Gardnerella vaginalis hemolysin and with prolidase and sialidase levels in women with bacterial vaginosis. J Infect Dis (2002) 0.90
Dietary supplementation with probiotics during late pregnancy: outcome on vaginal microbiota and cytokine secretion. BMC Microbiol (2012) 0.89
The aging gut microbiota: new perspectives. Ageing Res Rev (2011) 0.89
The application of the Ten Group classification system (TGCS) in caesarean delivery case mix adjustment. A multicenter prospective study. PLoS One (2013) 0.89
A comparison of dequalinium chloride vaginal tablets (Fluomizin®) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. Gynecol Obstet Invest (2011) 0.89
Variation in Nugent score and leukocyte count in fluid collected from different vaginal sites. Obstet Gynecol (2005) 0.88
Development of microparticulate systems for intestinal delivery of Lactobacillus acidophilus and Bifidobacterium lactis. Eur J Pharm Sci (2010) 0.88
In vitro fermentation of potential prebiotic flours from natural sources: impact on the human colonic microbiota and metabolome. Mol Nutr Food Res (2012) 0.87
Leukocytospermia and sperm preparation--a flow cytometric study. Reprod Biol Endocrinol (2009) 0.87
Postpartum urinary symptoms: prevalence and risk factors. Eur J Obstet Gynecol Reprod Biol (2002) 0.87
PCR detection of Bifidobacterium strains and Streptococcus thermophilus in feces of human subjects after oral bacteriotherapy and yogurt consumption. Int J Food Microbiol (2003) 0.87
Proteome profiles of vaginal fluids from women affected by bacterial vaginosis and healthy controls: outcomes of rifaximin treatment. J Antimicrob Chemother (2013) 0.87
Effects of Ureaplasma parvum lipoprotein multiple-banded antigen on pregnancy outcome in mice. J Reprod Immunol (2013) 0.86
Novel probiotic candidates for humans isolated from raw fruits and vegetables. Food Microbiol (2012) 0.86
Correlation of Atopobium vaginae Amount With Bacterial Vaginosis Markers. J Low Genit Tract Dis (2012) 0.86
Polymer-lipid based mucoadhesive microspheres prepared by spray-congealing for the vaginal delivery of econazole nitrate. Eur J Pharm Sci (2008) 0.86
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women. J Adolesc Health (2010) 0.86
Serum profiling of healthy aging identifies phospho- and sphingolipid species as markers of human longevity. Aging (Albany NY) (2014) 0.86
Human chorionic gonadotropin (hCG) and prevention of breast cancer. Mol Cell Endocrinol (2007) 0.85
IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation. Gut Microbes (2012) 0.85
Molecular and phenotypic traits of in-vitro-selected mutants of Bifidobacterium resistant to rifaximin. Int J Antimicrob Agents (2008) 0.85
p53 at codon 72 polymorphism, human papillomavirus infection and cervical lesions: a cross-sectional study from northeastern Italy. Eur J Obstet Gynecol Reprod Biol (2004) 0.84
The enterocyte-associated intestinal microbiota of breast-fed infants and adults responds differently to a TNF-α-mediated pro-inflammatory stimulus. PLoS One (2013) 0.84
Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans. Thromb Res (2003) 0.83
Bacterial vaginosis and preterm delivery: an open question. J Reprod Med (2005) 0.83
Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitis-associated colorectal cancer acting on Notch signaling and gut microbiota. Int J Cancer (2014) 0.83
Combination of vaginal pH with vaginal sialidase and prolidase activities for prediction of low birth weight and preterm birth. Am J Obstet Gynecol (2005) 0.83